Key Findings
SonoThera has successfully closed a Series B financing round, raising $125 million. This capital infusion is dedicated to accelerating the clinical development of its gene therapy programs targeting Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD). A central focus of this funding is to advance the company’s proprietary ultrasound-mediated gene delivery technology, which operates without the use of viral vectors.
Technical / Clinical Details
- Ultrasound-Mediated Delivery Technology: At the core of SonoThera’s approach is its innovative technology that leverages focused ultrasound energy to non-invasively deliver genetic material (such as DNA or RNA) directly to target tissues and cells. This method is designed to overcome safety concerns associated with widely used viral vectors (e.g., AAV) in current gene therapies, including immunogenicity, off-target effects, and manufacturing complexities.
- DMD Program: Duchenne muscular dystrophy is a severe genetic disorder caused by mutations in the dystrophin gene, leading to progressive muscle degeneration. SonoThera aims to deliver functional dystrophin or micro-dystrophin genes to muscle cells using its ultrasound technology, with the goal of halting or slowing disease progression.
- ADPKD Program: Autosomal dominant polycystic kidney disease (ADPKD) is a common inherited disorder where numerous cysts form in the kidneys, ultimately leading to kidney failure. The company is developing an approach to deliver therapeutic genes targeting the underlying causes of ADPKD to specific kidney cells, facilitated by ultrasound.
- Improved Safety Profile: The non-viral nature of SonoThera’s delivery system is expected to significantly reduce the risk of severe immune responses often associated with viral vectors, potentially leading to a safer therapeutic profile. This is a critical advantage for long-term gene therapy applications.
Background & Context
Gene therapy holds transformative potential for treating the root causes of diseases, but the reliance on viral vectors for delivery has presented significant challenges, including safety concerns, high manufacturing costs, and limitations on redosing. These obstacles have historically hindered the commercialization and widespread patient access to gene therapies. Non-viral delivery platforms like SonoThera’s represent a promising avenue to overcome these constraints, offering a safer and more flexible approach that could revolutionize the gene therapy landscape.
Strategic Significance & Outlook
With the $125 million Series B financing, SonoThera is poised to advance its gene therapy programs for two high-unmet-need diseases, DMD and ADPKD, into clinical development. The non-invasive and high-safety profile of its ultrasound-mediated delivery technology suggests broad applicability for various genetic and chronic diseases in the future. This funding round demonstrates strong confidence in the company’s technology to play a pivotal role in shaping the future of gene therapy, further establishing ultrasound-mediated gene delivery as a significant emerging therapeutic modality.
Source: https://www.biospace.com/business/sonothera-bags-125m-series-b-to-advance-safer-gene-therapies
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments